A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

1. Tiwari J. Navigating through orphan medicinal product regulations in EU and US—similarities and differences. Regul Toxicol Pharmacol. 2015;71(1):63–67. 2. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010;9(12): 921–929. 3. Kakkis ED, O’Donovan M, Cox G, et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J Rare Dis. 2015;10:16. doi:10.1186/s13023-014-0195-4 4. Gaddipati H, Liu K, Pariser A, Pazdur R. Rare cancer trial design: lessons from FDA approvals. Clin Cancer Res. 2012;18: 5172–5178. 5. Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4): 488–496. 6. Braun MM, Farag-El-Massah S, Xu K, Cot e TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010;9:519–522. 7. Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012;17(13–14):660–664. 8. Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821–825. 9. Orphan Drug Act. 21 CFR Part 316 Orphan Drugs. US Food Drug Admin. 2013;78(113):15–33. 10. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6(1):42. 11. Bashaw ED, Huang S-M, Cot e TR, et al. Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov. 2011;10(11):795–796. 12. Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol. 2014;21(1):66–78. 13. Oo C, Tsai J-C, Kao HD. There is no better time than the present: nanotechnology as a disruptive innovation for drug development. Drug Discov Today. 2015;20(6):645–647. 14. Dunoyer M. Accelerating access to treatments for rare diseases. Nat Rev Drug Discov. 2011;10(7):475–476. Oo and Rusch 3 Drug Interactions